Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 04/12/2024 at 19:32, 7 months 9 days ago

Formycon AG Announces Preliminary Financial Results for 2023 and Forecasts for 2024

Financial Results Biotechnology 2024 Guidance Formycon AG 2023 Forecast
BRIEF

published on 04/12/2024 at 19:32, 7 months 9 days ago

Formycon AG annonce ses résultats financiers préliminaires pour 2023 et ses prévisions pour 2024

Résultats Financiers Biotechnologie Formycon AG Prévisions 2023 Orientation 2024
PRESS RELEASE

published on 04/12/2024 at 19:27, 7 months 9 days ago

EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024

EBITDA 2023 Financial Year Formycon AG Preliminary Figures 2024 Financial Year
BRIEF

published on 04/11/2024 at 07:35, 7 months 10 days ago

Formycon and Bioeq Launch FYB201 in Canada and Switzerland

Biosimilar Formycon Bioeq FYB201 AMD Treatment
BRIEF

published on 04/11/2024 at 07:35, 7 months 10 days ago

Formycon et Bioeq lancent FYB201 au Canada et en Suisse

Formycon Bioeq EFB201 Traitement De La DMLA Biosimilaire
PRESS RELEASE

published on 04/11/2024 at 07:30, 7 months 10 days ago

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases

Ranibizumab Biosimilar Formycon FYB201 Commercial Launch
BRIEF

published on 03/18/2024 at 10:05, 8 months 3 days ago

Formycon and Fresenius Kabi Reach Settlement with Johnson & Johnson for FYB202 in Europe and Canada

Biosimilars Settlement Agreement Formycon Fresenius Kabi FYB202
BRIEF

published on 03/18/2024 at 10:05, 8 months 3 days ago

Formycon et Fresenius Kabi parviennent à un accord avec Johnson & Johnson pour FYB202 en Europe et au Canada

Formycon Fresenius Kabi FYB202 Entente De Règlement Biosimilaires
PRESS RELEASE

published on 03/18/2024 at 10:00, 8 months 3 days ago

Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options

Settlement Agreement Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 03/11/2024 at 07:35, 8 months 10 days ago

FYB201/Ranibizumab Gains Approval and Scheduled for Launch in the MENA Region

MENA Region Formycon AG MS Pharma Ranibizumab Diabetic Retinopathies

Accesswire

Published on 11/22/2024 at 00:00, 4 hours 41 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 6 hours 36 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 6 hours 51 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 8 hours 26 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 8 hours 31 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 9 hours 39 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 10 hours 5 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 10 hours 42 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 10 hours 49 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 10 hours 49 minutes ago

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.

Les Echos

Published on 11/21/2024 at 06:58, 21 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 21 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 21 hours 43 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 8 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 9 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE